Yousif Capital Management LLC cut its stake in Coherus BioSciences, Inc. (NASDAQ:CHRS – Free Report) by 9.8% during the 1st quarter, HoldingsChannel reports. The firm owned 36,858 shares of the biotechnology company’s stock after selling 3,990 shares during the quarter. Yousif Capital Management LLC’s holdings in Coherus BioSciences were worth $252,000 as of its most […]
Coherus BioSciences (NASDAQ:CHRS – Free Report) had its price target trimmed by HC Wainwright from $24.00 to $20.00 in a research report sent to investors on Thursday, MarketBeat reports. The firm currently has a buy rating on the biotechnology company’s stock. A number of other equities analysts also recently issued reports on the company. Barclays […]
First formal distribution agreement for YUSIMRY™, a biosimilar of Humira®, at $995 per carton (two 40 mg/0.8 mL autoinjectors) representing a discount of.
Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) saw a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 13,010,000 shares, an increase of 9.3% from the May 15th total of 11,900,000 shares. Based on an average daily volume of 1,990,000 shares, the short-interest ratio is […]